News | Radiation Therapy | July 05, 2019

Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones

Cones allow radiation therapy clinics to deliver stereotactic radiosurgery with existing general purpose radiotherapy equipment

Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones

July 5, 2019 — Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of patented SRS Cones globally for use in cancer treatments and other appropriate radiation therapies.

The use of calibrated cones in stereotactic radiosurgery has grown in recent years, particularly in clinics that do not have access to the most advanced special-purpose radiation treatment equipment. By using the Aktina SRS Cones, such clinics can deliver highly accurate SRS treatments using their existing general-purpose radiation treatment equipment.

Unlike previous solutions, the Aktina SRS Cone system features lead-based interlocking cones with stainless steel sleeves that have carved channels and grooves that match corresponding channels and grooves carved into the applicator. As each cone is inserted into the applicator, they depress (or don’t depress) specific switches, and confirm by their own insertion that they are the proper size cone for the programmed dosage. The control software, which has been integrated with the cones and applicator, compares the installed cone with the programmed plan and confirms they match before proceeding. In this way, automated treatment verification lets technicians benefit from fast, simple equipment setup while ensuring they deliver the correct dosage and treatment specified for the patients.

For more information: www.aktina.com, www.elekta.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.